Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203510 · ClinicalTrials.gov registry record · Phase 4
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
A Phase 4 study of Pulmonary Arterial Hypertension, sponsored by United Therapeutics.
- Active
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT05203510: Active Phase 4 study of Pulmonary Arterial Hypertension, sponsored by United Therapeutics.
NCT05203510 is a Phase 4 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by United Therapeutics. The registered enrollment target is 52 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05203510, a Phase 4 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by United Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Conditions Studied
Interventions
- DRUG Parenteral Treprostinil
- DRUG Oral Treprostinil
Study Locations (20)
California
- University of California San Francisco - Fresno - Fresno
- Cedars-Sinai Medical Center - Los Angeles
- University of California Davis Medical Center - Sacramento
- University of California San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine - San Francisco
Arizona
- Banner University Medical Center (University of Arizona) - Phoenix
- HonorHealth John C. Lincoln Medical Center - Phoenix
Indiana
- Indiana University Health North Hospital - Indianapolis
- Community Health Network - Indianapolis
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center - Durham
Connecticut
- Hartford Hospital - Hartford
Florida
- USF - Tampa
Georgia
- Georgia Clinical Research - Austell
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 4 |
What the registry record for NCT05203510 still lists
NCT05203510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Parenteral Treprostinil is the first listed.
NCT05203510 names 20 study sites across 14 states, led by California, Arizona, Indiana.
Frequently Asked Questions
What is clinical trial NCT05203510 about?
NCT05203510 is a clinical study titled "A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension". The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
What is the current status of trial NCT05203510?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2022-10-20. Estimated completion is 2028-04-30.
What conditions does trial NCT05203510 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT05203510?
The interventions under investigation include: Parenteral Treprostinil (DRUG), Oral Treprostinil (DRUG).
Who is sponsoring clinical trial NCT05203510?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05203510 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05203510's enrollment target sits among peer trials
52 31st of 63 higher than 33 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
COMPLETED · Phase 4
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
COMPLETED · Phase 4
-
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
COMPLETED · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI